A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation

Trial Profile

A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Cystic fibrosis; Pseudomonal infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Aug 2016 Status changed from recruiting to completed, as per an article published in the Antimicrobial Agents and Chemotherapy
    • 22 Aug 2016 Results published in the Antimicrobial Agents and Chemotherapy
    • 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top